Welcome to our dedicated page for Medtronic SEC filings (Ticker: MDT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The pacemakers, insulin pumps, and neurostimulators that power Medtronic’s reputation live inside millions of patients—and inside hundreds of dense SEC documents. Product recalls, FDA approvals, and global tax disclosures can stretch a single Medtronic annual report beyond 300 pages, leaving many investors asking ‘where do I find the real story?’
StockTitan answers that question the moment a document hits EDGAR. Our platform ingests every Medtronic 10-K, 10-Q, 8-K, and Form 4, then deploys AI-powered summaries so Medtronic SEC filings explained simply is more than a promise. Need Medtronic insider trading Form 4 transactions or a heads-up on director buys? Real-time alerts flag Medtronic Form 4 insider transactions real-time as they occur. Prefer big-picture context? AI pulls segment revenue and margin shifts straight from the latest Medtronic quarterly earnings report 10-Q filing and packages them into concise dashboards.
Dig deeper with one click: targeted tags guide you to R&D spend, international tax notes, and safety disclosures inside the Medtronic annual report 10-K simplified. Governance questions? The Medtronic proxy statement executive compensation view highlights pay-for-performance metrics, while Medtronic 8-K material events explained keeps you ahead of recalls or FDA warnings. Whether you’re comparing cash-flow trends, tracking Medtronic executive stock transactions Form 4, or seeking a fast Medtronic earnings report filing analysis, our AI delivers the clarity you need for confident decisions—understanding Medtronic SEC documents with AI has never been easier.
Medtronic plc reported the results of its Annual General Meeting held on October 16, 2025. Shareholders approved amendments to the company’s Memorandum and Articles of Association, including changes to Article 177 to allow the Board to capitalize certain non-distributable reserves to create distributable reserves and updates to the advance notice provisions. They also approved a capital reduction to create distributable reserves under Irish law.
All twelve director nominees were elected and shareholders ratified the appointment of PricewaterhouseCoopers LLP as independent auditor for fiscal 2026 and authorized the Board, through the Audit Committee, to set auditor remuneration. Shareholders renewed the Board’s authority to issue shares and to opt out of pre-emption rights under Irish law, and authorized the company and its subsidiaries to make overseas market purchases of ordinary shares. At the record date, 1,282,616,011 ordinary shares were outstanding; 1,109,198,321 were represented at the meeting, constituting a quorum.
Medtronic plc (MDT) appears on a Form 25 notification indicating the class of securities is being removed from listing and/or registration on the New York Stock Exchange LLC. The filing identifies the issuer's principal office at 710 Medtronic Pkwy, Minneapolis, MN and includes the Commission File Number 001-36820. The form cites compliance with 17 CFR 240.12d2-2 provisions for withdrawal or removal. The document provides no explanation of timing, underlying transaction, or impact on shareholders.
Medtronic plc filed an 8-K disclosing a Sixth Supplemental Indenture dated
Medtronic plc filed an 8-K disclosing an Underwriting Agreement dated
The notice identifies the existence and date of the underwriting arrangement and the lead underwriters but does not disclose transaction size, terms, or intended use of proceeds.
Medtronic plc is offering debt securities, including $750,000,000 aggregate principal amount of 4.200% senior notes due October 15, 2045. The prospectus supplement states certain pricing rows showing prices to investors near 99.97% with underwriting discounts of 0.35% and 0.65%, producing proceeds to Medtronic, Inc. around 99.62% and 99.25% respectively. As of July 25, 2025, the company reported approximately $28.6 billion of debt outstanding, including $27.8 billion aggregate principal of senior debt of Medtronic plc, Medtronic Luxco and Medtronic, Inc.
The supplement explains that Medtronic Luxco and Medtronic, Inc. are wholly‑owned indirect subsidiaries of Medtronic plc and that notes issued by Medtronic, Inc. will be fully and unconditionally guaranteed on a joint and several basis by Medtronic plc and Medtronic Luxco. The indenture does not prohibit additional unsecured indebtedness or significant secured indebtedness and certain tax, withholding and investor eligibility provisions are described. Financial statements for Luxco and Medtronic, Inc. are not separately included; Medtronic plc provides alternative summarized disclosure under Regulation S‑X.
Medtronic insider stock sales reported. The reporting person, EVP & President Cardiovascular Harry "Skip" Kiil, sold a total of 8,605 ordinary shares in two transactions on 09/03/2025 at prices of about $91.58 and $91.59. After these dispositions the reporting person beneficially owns 35,615 ordinary shares, held directly. The Form 4 was submitted to disclose these non-derivative sales and the change in beneficial ownership.
Medtronic (MDT) Form 144 summary: The filing notifies an intended sale of 8,605 shares of Medtronic common stock held at Fidelity Brokerage Services, with an aggregate market value of $788,048.74. The shares were acquired on 08/01/2025 through restricted stock vesting from the issuer as compensation and the filer lists an approximate sale date of 09/03/2025 on the NYSE. The filing states there were no other securities sold by the same person in the past three months and includes the standard representation that the seller is not aware of undisclosed material adverse information.
Medtronic (MDT) reported first-quarter fiscal 2026 operating details showing continued product-driven revenue growth across core portfolios and ongoing corporate actions. The company announced in May 2025 its intent to separate the Diabetes Operating Unit into a standalone public company, expected within 18 months. Cardiovascular net sales were up, with Cardiac Rhythm & Heart Failure rising 12%, Structural Heart & Aortic up 9%, and Coronary & Peripheral Vascular up 5%. Medical Surgical net sales were $2.1 billion, up 4% year-over-year. Research and development expense was $726 million versus $676 million a year earlier, and selling, general, and administrative expense was $2.8 billion versus $2.7 billion. The company recognized a $90 million fair-value loss on its Mozarc investment and recorded restructuring charges of $67 million. Deferred revenue was $442 million. Total debt was $28.6 billion while liquidity included $1.3 billion cash and $6.8 billion of current investments. Accrued litigation was approximately $0.2 billion; legal and tax matters remain disclosed as potentially material.
William R. Jellison, a director of Medtronic plc (MDT), reported two open-market purchases of ordinary shares. He acquired 2,500 shares on 08/22/2025 at $92.73 per share and 2,500 shares on 08/25/2025 at $92.37 per share, bringing his reported direct beneficial ownership to 5,000 shares. The filing notes the shares are held in a joint account with his spouse. The Form 4 was executed by an attorney-in-fact on 08/25/2025. No derivative transactions or dispositions are reported in this filing.
Medtronic plc (MDT) outlines FY25 operational and governance highlights in its 2025 Definitive Proxy Statement. The company reported $7.0 billion in cash flow from operations (up 4%) and $5.2 billion in free cash flow, representing a 73% conversion from non-GAAP net earnings. Medtronic returned $6.3 billion to shareholders via $3.6 billion in dividends and $2.7 billion in net share repurchases and announced a dividend increase for the 48th consecutive year. The company invested $2.7 billion in R&D, advanced an innovation pipeline with ~170 active clinical trials and ~130 regulatory approvals, and launched multiple products across portfolios. Medtronic reduced Class 1 and 2 recalls by 33% and announced intent to separate the Diabetes segment via IPO/split within 18 months.
FAQ
What is the current stock price of Medtronic (MDT)?
What is the market cap of Medtronic (MDT)?
